Alexandra Gerlach, Senior Content Producer

Pharmacists at the 2026 HOPA Annual Meeting discuss medical misinformation and how to combat it.

Experts discuss the 340B Pricing Program, sharing updates, ongoing challenges, and solutions for pharmacists.

Tarlatamab, a DLL3 T‑cell engager, advances treatment of extensive‑stage SCLC.

Insights from the 2026 HOPA Annual Conference highlight the pharmacist's role in operationalizing belantamab mafodotin.

FDA approves nivolumab with AVD for stage III/IV classical Hodgkin lymphoma, boosting PFS and redefining first-line care.

Daily walking and resistance bands during chemotherapy help curb chemo brain and brain fog, keeping patients active and sharper at home.

FDA approval expands the use of teclistamab plus daratumumab, which significantly improved survival in the MajesTEC-3 trial.

Emerging targets are reshaping how mCRPC is treated, as showcased at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Data presented at the 2026 ASCO Genitourinary Cancers Symposium show the benefit of enfortumab vedotin-ejfv plus pembrolizumab in muscle-invasive bladder cancer.

Capivasertib plus abiraterone improves survival in PTEN-deficient hormone-sensitive prostate cancer.

PEACE-3 trial data presented at ASCO GU show survival benefits with enzalutamide combination.

FDA approves encorafenib plus cetuximab chemotherapy for BRAF V600E metastatic colorectal cancer, boosting survival and response in BREAKWATER.

Study links GLP-1 receptor agonists plus progestin to lower endometrial cancer risk, hinting at new prevention and treatment paths with fewer hysterectomies.

FDA approval expands pembrolizumab (Keytruda) for PD‑L1+ platinum‑resistant ovarian cancer, pairing with paclitaxel ± bevacizumab to improve survival outcomes.

Experts discuss the role of pharmacists in CAR T-cell and gene therapy at the 2026 ASTCT Tandem Meeting in Salt Lake City.

Researchers develop a novel therapy combining molecular glues and KRAS inhibitors, showing promise in treating KRAS-mutant non–small cell lung cancer.

A long-term study reveals that high-fat cheese consumption may lower dementia risk, challenging traditional views on dietary fat and brain health.

Prolonged exposure to specific air pollution components significantly increases depression risk in older adults, highlighting the need for targeted regulations.

Sacituzumab govitecan shows promising overall survival trends in HR+/HER2− metastatic breast cancer, despite not meeting primary progression-free survival goals.

Ribociclib shows higher early treatment modifications than palbociclib in HR+/HER2– breast cancer, emphasizing the need for proactive toxicity management.

A UK research team has pioneered a blood test using infrared technology to detect lung cancer cells, promising earlier diagnoses and personalized treatments.

Measles cases surge in the US, prompting quarantine measures in South Carolina schools and raising urgent vaccination concerns amid declining rates.

The FDA-approved flibanserin represents the first and only once-daily oral pill for postmenopausal women with hypoactive sexual desire disorder.

Pharmacists play a vital role in modern clinical trials, enhancing patient safety and trial efficiency through drug management and protocol development.

SABCS 2025 showcases breakthroughs in breast cancer therapy, emphasizing novel therapies and precision medicine to enhance patient outcomes.

Pivotal FDA approvals in breast cancer treatment focused on precision medicine and innovative therapies in 2025.

Exploratory findings from the MONALEESA-3 trial presented at SABCS 2025 show ribociclib plus fulvestrant significantly enhances survival in ILC.

Discover how antibody drug conjugates (ADCs) are transforming treatment for HER2-positive breast cancer with brain metastases at SABCS 2025.

Experts explore the evolving role of HER2- and TROP2-targeted therapies in breast cancer treatment at SABCS 2025, highlighting ADC advancements.